Trial Profile
A Study Investigating Switch Failures in Patients who Underwent a Non-Medical Switch from Originator Etanercept (ETA, Enbrel) to the Biosimilar Etanercept (SB4, Benepali)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2017
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis; Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 18 Dec 2017 New trial record
- 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.